Immune Regulation News 10.43 November 9, 2018 | |
| |
TOP STORYThe Metabolite BH4 Controls T Cell Proliferation in Autoimmunity and Cancer Investigators found that genetic inactivation of GTP cyclohydrolase 1 and inhibition of sepiapterin reductase severely impaired the proliferation of mature mouse and human T cells. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists describe the existence of a CD301b+ perivascular dendritic cell subset that continuously samples blood and relays antigens to neighboring mast cells, which vigorously degranulate and trigger anaphylaxis. [Science] Abstract | Press Release Tumor Immunoevasion via Acidosis-Dependent Induction of Regulatory Tumor-Associated Macrophages Researchers explored a molecular mechanism of metabolic communication deployed by highly glycolytic tumors for immunoevasion. In contrast to colon adenocarcinomas, melanomas showed comparatively high glycolytic activity, which resulted in high acidification of the tumor microenvironment. [Nat Immunol] Abstract Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis Scientists found that psoriasis-affected skin lesions program interleukin-17-producing T cells in draining lymph nodes to home to distal skin and later to arteries. [Cell Metab] Abstract | Press Release | Graphical Abstract Researchers showed that inhibiting inflammation reduced and promoting it accelerated axonal regeneration in spinal-lesioned zebrafish larvae. Mutant analyses showed that peripheral macrophages, but not neutrophils or microglia, were necessary for repair. [Nat Commun] Full Article | Press Release B Cell Receptor Crosslinking Augments Germinal Center B Cell Selection when T Cell Help Is Limiting By adapting an experimental approach that enables independent delivery of B cell receptor-crosslinking antigen or T cell help to germinal center (GC) B cells in vivo, the authors showed that T cell help was sufficient to induce GC B cell expansion and plasmablast formation. [Cell Rep] Full Article | Graphical Abstract Genetic Models Reveal cis and trans Immune-Regulatory Activities for lincRNA-Cox2 Investigators characterized multiple models of long intergenic non-coding RNA (lincRNA)-Cox2-deficient mice. LincRNA-Cox2-deficient macrophages and murine tissues had altered expression of inflammatory genes. [Cell Rep] Full Article | Press Release | Graphical Abstract VISTA Expressed in Tumor Cells Regulates T Cell Function Scientists investigated V-domain Ig suppressor of T cell activation (VISTA) expression and function in tumor cells, and evaluated its mechanism and activity. [Br J Cancer] Full Article The authors interrogated the B cell signals required for transitional B cell transmembrane activator and CAML interactor (TACI) expression and Ab production. Surprisingly, despite established roles for dual BCR and TLR signals in autoantibody (autoAb) production in systemic lupus erythematosus, signals downstream of these receptors exerted distinct impacts on transitional B cell TACI expression and autoAb titers. [J Immunol] Abstract Investigators showed that for four days following activation, mouse CD4+ T cells sustained their commitment to glycolysis facilitated by increased glucose uptake through increased expression of GLUT transporters. [J Immunol] Abstract Treg cell depletion was achieved by treatment of transgenic C57BL/6DTR/eGFP mice with diphtheria toxin after three weeks of intratracheal infection with 1×106 Paracoccidioides brasiliensis yeasts. [Sci Rep] Full Article Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News. | |
| |
REVIEWSHypoxia-Inducible Factor-1α Regulation of Myeloid Cells Researchers summarize recent advances that have elucidated the mechanism by which myeloid cells regulate hypoxia-inducible factor (HIF)-1α activity and, in turn, how HIF-1α shapes myeloid cell function. [J Mol Med] Abstract Visit our reviews page to see a complete list of reviews in the immune regulation research field. | |
| |
SCIENCE NEWSOncoMed Announces Early Clinical Data for Anti-TIGIT Antibody OncoMed Pharmaceuticals, Inc. announced initial results from the Phase Ia dose escalation portion of a Phase Ia/b trial of etigilimab, the company’s anti-TIGIT antibody. [Press release from OncoMed Pharmaceuticals, Inc. discussing research presented at the 2018 Society for Immunotherapy of Cancer (SITC) Meeting, Washington] Press Release From August 2017 to October 2018, safety and efficacy clinical trials were completed using a novel first-in-human combination immunotherapy cancer vaccine. [Press release from NantKwest discussing research presented at the 2018 Society for Immunotherapy of Cancer (SITC) Meeting, Washington] Press Release Merck announced the first presentations of preliminary safety and efficacy data from Phase I/II dose finding studies for the company’s investigational anti-LAG-3 therapy and anti-TIGIT therapy in patients with advanced solid tumors. [Press release from Merck & Co., Inc. discussing research presented at the 2018 Society for Immunotherapy of Cancer (SITC) Meeting, Washington] Press Release Synlogic, Inc. announced the presentation of preclinical data from its first immuno-oncology program. [Press release from Synlogic, Inc. discussing research presented at the 2018 Society for Immunotherapy of Cancer (SITC) Meeting, Washington] Press Release X4 Pharmaceuticals highlighted data from a poster presentation of a clinical study with X4P-001-IO, an investigational CXCR4 allosteric antagonist. [Press release from X4 Pharmaceuticals discussing research presented at the 2018 Society for Immunotherapy of Cancer (SITC) Meeting, Washington] Press Release | |
| |
INDUSTRY NEWSLilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines Eli Lilly and Company and NextCure, Inc. announced a multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer targets utilizing NextCure’s proprietary FIND-IO™ platform. [Eli Lilly and Company] Press Release Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics IRX Therapeutics, Inc. announced that the company’s assets have been acquired by the newly formed Brooklyn ImmunoTherapeutics LLC. This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a range of cancers. [Brooklyn ImmunoTherapeutics] Press Release Visterra Initiates Phase I Clinical Study of VIS649 Visterra, Inc. announced the initiation of a Phase I clinical study with VIS649 in healthy volunteers. [Visterra, Inc.] Press Release Mirati Therapeutics, Inc. announced dosing of the first patient under its collaboration agreement with BeiGene, Ltd. in a Phase Ib clinical trial to assess the safety and tolerability, pharmacokinetics and preliminary anti-tumor activity of Mirati’s sitravatinib in combination with BeiGene’s investigational anti-PD1 antibody, tislelizumab, in patients with advanced solid tumors. [Mirati Therapeutics, Inc.] Press Release | |
| |
POLICY NEWSSanger Whistle-Blowers Dispute Findings That Cleared Management of Bullying Current and former employees say investigation at the Wellcome Sanger Institute was flawed; the genomics powerhouse stands by the findings. [Nature News] Editorial Scientists Struggle with Confusing Journal Guidelines Globally, more than two-thirds of researchers find it difficult to prepare manuscripts and to respond to peer-review comments, finds a survey of nearly 7,000 researchers from over 100 countries. [Nature News] Editorial Open-Access Plan Draws Online Protest Hundreds of scientists are pushing back against Plan S, a plan to crack down on scholarly journals’ paywalls, launched 2 months ago by 11 national research funders in Europe. In an open letter published on 5 November, about 800 signatories say they support open access—making papers available free to all readers online—but condemn Plan S as “too risky for science.” [ScienceInsider] Editorial
| |
EVENTSNEW Keystone Symposia: Skin Health and Disease: Immune, Epithelial and Microbiome Crosstalk Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW PhD Position – Cancer Immunotherapy (Helmholtz Zentrum München) Research Technologist – Immunology (STEMCELL Technologies Inc.) Senior Lab Manager – Cellular Immunology and Rheumatology (Karolinska Institutet) Tenure/Tenure Track Faculty Position – Immunology (Wayne State University) Postdoctoral Fellow – Immunology (Johns Hopkins University) PhD Position – Antigen Presentation and Immune Regulation (Erasmus MC) Postdoctoral Fellow – Immunology (Mondor Biomedical Research Institute) Postdoctoral Research Associate – Molecular Mechanisms of Innate Immunity (University of Illinois) Open Rank Professor – Biopharmaceutical Discovery (University of Delaware) Assistant Professor – Biology (University of Delaware) Head of Laboratory – Immunology of Regulatory T Cells (Novartis Pharma AG) Postdoctoral Fellowship – Immunology (University of Nantes) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Immune Regulation News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|